<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328393</url>
  </required_header>
  <id_info>
    <org_study_id>2005-000570-52</org_study_id>
    <nct_id>NCT00328393</nct_id>
  </id_info>
  <brief_title>Effect of Pioglitazone on Ambulatory Blood Pressure</brief_title>
  <official_title>Effect of Pioglitazone on Ambulatory Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <brief_summary>
    <textblock>
      The anti-diabetic pioglitazone has been found to reduce casual blood pressure. To date, no
      data are available looking at this effect in detail. Especially, ambulatory blood pressure
      has not yet been utilized to confirm the hypothesis that pioglitazone has blood pressure
      lowering effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median of systolic 24-hour ambulatory blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of 24-hour blood pressure after 8 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median of 24-hour diastolic ambulatory blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of 24-hour diastolic blood pressure after 8 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone 45 mg, 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>45 mg 8 weeks</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 45-75 years

          -  Diabetes mellitus Type 2 (HbA1c 7 - 8.5%)

          -  Casual blood pressure &gt; = 130/80 mmHg, &lt; 160/100 mmHg

        Exclusion Criteria:

          -  Therapy with insulin

          -  Combination therapy of sulfonyl-urea und metformin

          -  Therapy with nateglinid, repaglinid or an other substance of this drug family

          -  Allergy against pioglitazone or other composites of the tablet

          -  History of heart failure (NYHA I bis IV)

          -  Hepatic insufficiency

          -  Transaminases &gt; 2.5-fold of the upper normal limit

          -  End-stage renal failure

          -  Syndrome of polycystic ovaries

          -  Absence of effective contraception in women of childbearing potential

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland E Schmieder, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-Nürnberg, Medical Department 4</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRC Medical Department IV</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2006</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

